Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
Cymabay Therapeutics Inc:
Cymabay Therapeutics Inc:
BRIEF-Cymabay Says Engine Capital Management Nominated 3 Candidates To Stand For Election To Board
09:34pm, Friday, 13'th Mar 2020
Cymabay Therapeutics Inc:
CymaBay Therapeutics Comments on Engine Capital Director Nominations
09:29pm, Friday, 13'th Mar 2020
NEWARK, Calif.,--(BUSINESS WIRE)--CymaBay Therapeutics, Inc. (NASDAQ: CBAY) (the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic
Benzinga's Top Upgrades, Downgrades For March 13, 2020
02:20pm, Friday, 13'th Mar 2020
Upgrades * Northland upgraded the stock for Advanced Micro Devices Inc (NASDAQ: AMD) from Market Perform to Outperform. For the fourth quarter, Advanced Micro Devices had an EPS of $0.32, compared t
CymaBay Therapeutics Inc (CBAY) Q4 2019 Earnings Call Transcript
01:30pm, Friday, 13'th Mar 2020
CBAY earnings call for the period ending December 31, 2019.
Goldman sees 143% upside in Amarin in premarket analyst action
11:26am, Friday, 13'th Mar 2020
IDEAYA Biosciences (NASDAQ:IDYA) initiated with Buy rating and $12 (192% upside) price target at Roth Capital.Menlo Therapeutics (NASDAQ:MNLO) resumed with Overweight rating and $15 (466% upside) at C
CymaBay Therapeutics (NASDAQ:CBAY) Upgraded to "Buy" at Oppenheimer
06:56am, Friday, 13'th Mar 2020
CymaBay Therapeutics (NASDAQ:CBAY) was upgraded by Oppenheimer to a “buy” rating in a research note issued to investors on Thursday, TipRanks reports. The brokerage presently has a $4.00 price obj
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q4 2019 Results - Earnings Call Transcript
03:24am, Friday, 13'th Mar 2020
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q4 2019 Results Earnings Conference Call March 12, 2020, 04:30 PM ET Company Participants Dan Menold - Vice President,
Why Did Oppenheimer Upgrade CymaBay Therapeutics’ Stock?
03:09am, Friday, 13'th Mar 2020
In a report released yesterday, Jay Olson from Oppenheimer upgraded CymaBay Therapeutics (CBAY – Research Report) to Buy, with a
Cantor Fitzgerald Upgrades CymaBay Therapeutics to Overweight, Raises Price Target to $5
12:00am, Friday, 13'th Mar 2020BRIEF-Cymabay Reports Q4 Loss Per Share $0.43
10:09pm, Thursday, 12'th Mar 2020
Cymabay Therapeutics Inc:
CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update
08:01pm, Thursday, 12'th Mar 2020
Investigating unexpected findings from Phase 2b study of seladelpar in NASH In parallel, board and management evaluating all potential strategic alternatives to maximize.
CymaBay Therapeutics, Inc. to Host Earnings Call
06:30pm, Thursday, 12'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / CymaBay Therapeutics, Inc. (NASDAQ:CBAY) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020
Intercept Pharmaceuticals: A High-Risk High-Gain Pick For 2020
03:30pm, Thursday, 12'th Mar 2020
Ocaliva continues to report solid uptake in PBC indication. FDA approval of OCA in NASH indication will open up much bigger market. However, an unfavourable FDA
